Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma, Non-Hodgkin 7Neoplasms 3Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 2Carcinoma, Non-Small-Cell Lung 2Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Renal Insufficiency 1Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Extranodal NK-T-Cell 1Hepatic Insufficiency 1HER2 Positive Breast Cancer 1Gallbladder Neoplasms 1Digestive System Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Carcinoma, Endometrioid 1

Interventions

pembrolizumab 3Nivolumab 2vicriviroc 1relatlimab 1copanlisib 1binimetinib 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Spinocerebellar Degenerations × copanlisib × Clear all
NCT03711058 2025-09-16

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
48 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Spinocerebellar Degenerations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡